OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jingyu Jiang, Haitao Huang, Ruihan Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Jingyu Jiang, Haitao Huang, Ruihan Chen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Showing 18 citing articles:
LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets
Zhiqing Xiang, Xiangli Yin, Leiyan Wei, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 187-187
Open Access | Times Cited: 8
Zhiqing Xiang, Xiangli Yin, Leiyan Wei, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 187-187
Open Access | Times Cited: 8
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 909-923
Open Access | Times Cited: 15
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 909-923
Open Access | Times Cited: 15
Cirrhosis and complications hepatocellular carcinoma – expanding indications for immunotherapy
Helena Degroote
Acta Clinica Belgica (2025), pp. 1-7
Closed Access
Helena Degroote
Acta Clinica Belgica (2025), pp. 1-7
Closed Access
Reversing NK cell exhaustion: a novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma
Yuxiang Huang, Hengjian Liao, Jiefu Luo, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Yuxiang Huang, Hengjian Liao, Jiefu Luo, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma
Wei Deng, Jin Xie, Tao Wang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Wei Deng, Jin Xie, Tao Wang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Approach to immunotherapy for HCC in the liver transplant population
Peter D. Block, Mario Strazzabosco, Ariel Jaffe
Clinical Liver Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Peter D. Block, Mario Strazzabosco, Ariel Jaffe
Clinical Liver Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
New Scenarios in Liver Transplantation for Hepatocellular Carcinoma
Ezequiel Mauro, Manuel Rodríguez‐Perálvarez, Antonio D’Alessio, et al.
Liver International (2024)
Open Access | Times Cited: 2
Ezequiel Mauro, Manuel Rodríguez‐Perálvarez, Antonio D’Alessio, et al.
Liver International (2024)
Open Access | Times Cited: 2
Immunofluorescence-Verified Sphingolipid Signatures Indicate Improved Prognosis in Liver Cancer Patients
Lujuan Pan, Huijuan Huang, Pengpeng Zhang, et al.
Journal of Cancer (2024) Vol. 15, Iss. 19, pp. 6239-6255
Open Access | Times Cited: 1
Lujuan Pan, Huijuan Huang, Pengpeng Zhang, et al.
Journal of Cancer (2024) Vol. 15, Iss. 19, pp. 6239-6255
Open Access | Times Cited: 1
Calpain 2 promotes Lenvatinib resistance and cancer stem cell traits via both proteolysis-dependent and independent approach in hepatocellular carcinoma
Xiaolu Ma, Kaixia Zhou, Tianqing Yan, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 1
Xiaolu Ma, Kaixia Zhou, Tianqing Yan, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 1
Immunotherapy for transplantation of hepatocellular carcinoma: the next frontier in adjunctive therapy
Parissa Tabrizian, Marcus Zeitlhoefler, Ahmed Talaat Hassan, et al.
Current Opinion in Organ Transplantation (2023) Vol. 29, Iss. 2, pp. 144-154
Closed Access | Times Cited: 3
Parissa Tabrizian, Marcus Zeitlhoefler, Ahmed Talaat Hassan, et al.
Current Opinion in Organ Transplantation (2023) Vol. 29, Iss. 2, pp. 144-154
Closed Access | Times Cited: 3
Emerging treatment strategies in hepatobiliary cancer
Deniz Can Güven, Hasan Çağrı Yıldırım, Elvin Chalabiyev, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 3, pp. 243-256
Closed Access | Times Cited: 2
Deniz Can Güven, Hasan Çağrı Yıldırım, Elvin Chalabiyev, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 3, pp. 243-256
Closed Access | Times Cited: 2
Harnessing the Power of Immunotherapy in Liver Transplantation for HCC
Dalal Alhaqqan, Yii Chun Khiew, Maryam Dadashzadeh, et al.
Current Transplantation Reports (2024) Vol. 11, Iss. 3, pp. 131-139
Closed Access
Dalal Alhaqqan, Yii Chun Khiew, Maryam Dadashzadeh, et al.
Current Transplantation Reports (2024) Vol. 11, Iss. 3, pp. 131-139
Closed Access
Significant Association of PD‐L1 With CD44 Expression and Patient Survival: Avenues for Immunotherapy and Cancer Stem Cells Downregulation in Pancreatic Cancers
Saleema Mehboob Ali, Adnan Ali, Zubair Ahmad, et al.
Journal of Cancer Epidemiology (2024) Vol. 2024, Iss. 1
Open Access
Saleema Mehboob Ali, Adnan Ali, Zubair Ahmad, et al.
Journal of Cancer Epidemiology (2024) Vol. 2024, Iss. 1
Open Access
The Role of Liver Transplantation in Hepatocellular Carcinoma
Neha Jakhete, Nehna Abdul Majeed, Daniel G. Maluf, et al.
Clinics in Liver Disease (2024) Vol. 29, Iss. 1, pp. 73-85
Closed Access
Neha Jakhete, Nehna Abdul Majeed, Daniel G. Maluf, et al.
Clinics in Liver Disease (2024) Vol. 29, Iss. 1, pp. 73-85
Closed Access
Transplant oncology and immunotherapy: Immunotherapy and liver transplants
Maen Abdelrahim, Abdullah Esmail
Elsevier eBooks (2024), pp. 87-105
Closed Access
Maen Abdelrahim, Abdullah Esmail
Elsevier eBooks (2024), pp. 87-105
Closed Access
Suppressing, stimulating and/or inhibiting: the evolving management of HCC patient after liver transplantation
Lorenza Di Marco, Adriana Romanzi, Alessandra Pivetti, et al.
Critical Reviews in Oncology/Hematology (2024), pp. 104607-104607
Closed Access
Lorenza Di Marco, Adriana Romanzi, Alessandra Pivetti, et al.
Critical Reviews in Oncology/Hematology (2024), pp. 104607-104607
Closed Access
Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review
Miho Akabane, Yuki Imaoka, Jun Kawashima, et al.
Journal of Liver Transplantation (2024), pp. 100256-100256
Open Access
Miho Akabane, Yuki Imaoka, Jun Kawashima, et al.
Journal of Liver Transplantation (2024), pp. 100256-100256
Open Access
Sequential Regorafenib or Nivolumab Therapy in Recurrent Hepatocellular Carcinoma with Sorafenib Failure in Liver Transplant Patients Does Not Improve Prognosis
Jieun Kwon, Jong Man Kim, Sang Oh Yun, et al.
(2023)
Open Access
Jieun Kwon, Jong Man Kim, Sang Oh Yun, et al.
(2023)
Open Access
Sequential regorafenib or nivolumab therapy in recurrent hepatocellular carcinoma with sorafenib failure in liver transplant patients does not improve prognosis
Jieun Kwon, Jong Man Kim, Jinsoo Rhu, et al.
Annals of Liver Transplantation (2023) Vol. 3, Iss. 2, pp. 104-112
Open Access
Jieun Kwon, Jong Man Kim, Jinsoo Rhu, et al.
Annals of Liver Transplantation (2023) Vol. 3, Iss. 2, pp. 104-112
Open Access
